ESMO Congress 2023 | OncologyPRO

Abstract 2048P

Background

Oxycodone is known to have numerous drug-drug interactions (DDIs) that can potentially decrease efficacy or lead to adverse drug reactions (ADRs). However, there is limited research on the frequency of DDIs associated with oxycodone use in patients with cancer. In this study, the frequency and pharmacological and clinical relevance of DDIs between oxycodone and perpetrators were studied in patients with cancer.

Methods

A cross-sectional study was conducted using pharmacy records to study the concomitant use of oxycodone and DDI perpetrators. These perpetrators were registered from oxycodone use trajectories between 1 September 2021 and 1 September 2022 in the Deventer Hospital by consulting Lexicomp®, Micromedex®, the Dutch Kennisbank and the Dutch Commentaren Medicatiebewaking. The clinical relevance of the identified perpetrators was examined by a clinical pharmacologist and a medical oncologist. Additionally, the frequency of multiple interactions was studied.

Results

In 254 oxycodone trajectories, 227 (89.4%) were found to include at least one pharmacologically relevant perpetrator. Of these, 210 (82.7%) were clinically relevant. A total of 80 different pharmacologically relevant perpetrators were identified, with 65 (81.3%) being considered clinically relevant. Interactions were observed in 21 (8.3%) oxycodone trajectories. Dutch compendia generally classified DDIs with oxycodone as less relevant compared to Lexicomp and Micromedex.

Conclusions

A high frequency of pharmacologically and clinically relevant perpetrators of DDIs with oxycodone was observed in our cohort. Moreover, a high number of double interactions involving oxycodone was found. Revision of drug interaction compendia used in Dutch healthcare in accordance with international compendia is recommended to improve pharmacovigilance.